SCHEMBL30955392

SCHEMBL30955392

CC(C)(C)OC(=O)Nc1ccnc(CSC2CCCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.43
▸ BACE1 P56817 2/20 0.43
▸ SREBF2 Q12772 1/20 0.41
▸ RORC P51449 3/20 0.40
▸ CYP17A1 P05093 2/20 0.40
▸ ATR Q13535 1/20 0.40
▸ QRFPR Q96P65 2/20 0.38
▸ ANO1 Q5XXA6 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ACACB O00763 1/20 0.37
▸ ACACA Q13085 1/20 0.37
▸ MAPKAPK2 P49137 1/20 0.37
▸ LNPEP Q9UIQ6 1/20 0.37
▸ MAPK14 Q16539 1/20 0.36
▸ ACSS2 Q9NR19 1/20 0.36
▸ DGAT1 O75907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30955403 0.98 CYP17A1 (0.42) ACHEBACE1SREBF2RORCCYP17A1
SCHEMBL30530884 0.83 SREBF2 (0.45) ACHEBACE1SREBF2CYP17A1ATR
SCHEMBL30955460 0.81 SREBF2 (0.46) SREBF2CYP17A1ATRMAPKAPK2ACSS2
SCHEMBL30955394 0.80 SREBF2 (0.43) SREBF2CYP17A1ATRMAPKAPK2MAPK14
SCHEMBL30955393 0.79 SREBF2 (0.42) ACHEBACE1SREBF2CYP17A1ATR
SCHEMBL23168284 0.79 SREBF2 (0.47) ACHEBACE1SREBF2CYP17A1ATR
SCHEMBL30955414 0.78 ATR (0.49) ACHEBACE1SREBF2CYP17A1ATR
SCHEMBL30955402 0.77 ATR (0.42) ACHEBACE1SREBF2CYP17A1ATR
SCHEMBL6591045 0.75 SREBF2 (0.49) SREBF2CYP17A1ATRMAPKAPK2ACSS2
SCHEMBL30955481 0.75 SREBF2 (0.44) SREBF2CYP17A1ATRMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024131938-A1 QUINAZOLINE COMPOUND AND USE THEREOF 赛诺哈勃药业(成都)有限公司 2024-06-27 — — WO disclosed
Send feedback